GICS Sector : Healthcare
PharmaSGP Holding SE manufactures over-the-counter drugs, and other healthcare products in Germany.The company's pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage cream for the treatment of different pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Fulminan, a beauty drink for problems in areas, such as eye area, buttocks, or thighs; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo.It also offers products for the treatment of chronic indications, including pain and other age-related ailments.
Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.
Can PharmaSGP Holding SE (HMSE:PSG) Maintain Its Strong Returns?
Aug -20
PharmaSGP Holding SE Holds 2025 Annual General Meeting
Jun -26
PharmaSGP Holding (ETR:PSG) Is Paying Out Less In Dividends Than Last Year
May -17
Discovering Europe's Hidden Stock Gems This April 2025
Apr -08
European Dividend Stocks To Watch Now
Apr -02
Discovering Undiscovered Gems on None in February 2025
Feb -04
Premier Dividend Stocks To Consider In January 2025
Jan -24
Discover 3 Hidden Small Cap Gems with Promising Potential
Jan -06
Health Brands from PharmaSGP Holding SE's 6% growth is driven by increasing demand for over-the-counter (OTC) medications, expansion into emerging markets, and strategic acquisitions. Additionally, the company's focus on digitalization, e-commerce, and product innovation are contributing to its growth. Furthermore, the rising trend of self-care and preventive healthcare is also boosting the demand for Health Brands' products.
PharmaSGP Holding SE's Beauty Brands segment growth is driven by increasing demand for natural and organic products, expansion into emerging markets, strategic acquisitions, and a strong online presence. Additionally, the segment benefits from a growing middle class, increasing consumer spending on beauty and personal care, and a focus on product innovation and diversification.
A proton pump inhibitor used to treat conditions such as gastroesophageal reflux disease (GERD) and ulcers.
A proton pump inhibitor used to treat conditions such as gastroesophageal reflux disease (GERD) and Zollinger-Ellison syndrome.
A proton pump inhibitor used to treat conditions such as gastroesophageal reflux disease (GERD) and erosive esophagitis.
A proton pump inhibitor used to treat conditions such as gastroesophageal reflux disease (GERD) and duodenal ulcers.
A proton pump inhibitor used to treat conditions such as gastroesophageal reflux disease (GERD) and duodenal ulcers.
A proton pump inhibitor used to treat conditions such as gastroesophageal reflux disease (GERD) and erosive esophagitis.
The threat of substitutes for PharmaSGP Holding SE is moderate due to the presence of alternative treatments and therapies.
The bargaining power of customers is low due to the specialized nature of PharmaSGP Holding SE's products and the lack of substitutes.
The bargaining power of suppliers is moderate due to the presence of multiple suppliers and the company's ability to negotiate prices.
The threat of new entrants is high due to the growing demand for pharmaceuticals and the increasing number of new market entrants.
The intensity of rivalry is high due to the presence of established competitors and the high stakes in the pharmaceutical industry.
| Value | |
|---|---|
| Debt Weight | 64.91% |
| Debt Cost | 4.13% |
| Equity Weight | 35.09% |
| Equity Cost | 4.13% |
| WACC | 4.13% |
| Leverage | 184.95% |
Value: 3.9
Growth: 6.6
Quality: 9.0
Yield: 2.5
Momentum: 4.0
Volatility: 7.0
1-Year Total Return ->
Value: 6.8
Growth: 7.9
Quality: 5.1
Yield: 1.9
Momentum: 4.0
Volatility: 6.3
1-Year Total Return ->
Value: 1.8
Growth: 6.6
Quality: 8.1
Yield: 3.1
Momentum: 0.5
Volatility: 5.0
1-Year Total Return ->
Value: 3.1
Growth: 8.9
Quality: 4.7
Yield: 0.6
Momentum: 2.0
Volatility: 1.3
1-Year Total Return ->
Value: 9.0
Growth: 2.3
Quality: 2.9
Yield: 0.0
Momentum: 3.5
Volatility: 1.0
1-Year Total Return ->
Value: 3.6
Growth: 4.0
Quality: 2.5
Yield: 0.0
Momentum: 2.5
Volatility: 1.0
1-Year Total Return ->